HCM has been the topic of a number of other reports. Zacks Investment Research upgraded HUTCHISON CHINA/S from a “sell” rating to a “hold” rating in a research note on Wednesday, March 6th. ValuEngine lowered HUTCHISON CHINA/S from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Deutsche Bank initiated coverage on HUTCHISON CHINA/S in a research report on Monday, March 4th. They set a “buy” rating and a $26.82 target price for the company. Finally, HSBC initiated coverage on HUTCHISON CHINA/S in a research report on Wednesday, March 27th. They set a “buy” rating for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $26.82.
Shares of NASDAQ:HCM traded down $0.39 during midday trading on Thursday, reaching $29.25. 125,700 shares of the company traded hands, compared to its average volume of 162,777. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.19 and a current ratio of 4.33. HUTCHISON CHINA/S has a 12 month low of $20.83 and a 12 month high of $39.68. The firm has a market cap of $3.96 billion, a price-to-earnings ratio of -51.32 and a beta of 1.11.
About HUTCHISON CHINA/S
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Further Reading: What is the Dividend Aristocrat Index?
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.